impaired fasting glucose clinical trials results

error versus placebo
STOP-NIDDM (Chiasson), 2002	acarbose 100mg three times daily versus placebo	patients with impaired glucose tolerance (WHO 1985 criteria)	double blind Follow-up duration: 3.3 years Canada, Germany, Austria, Nordic countries, Spain, Israel
insulin glargine versus placebo
GRACE - ORIGIN (glargine), 2012	insulin glargine (with a target fasting blood glucose level of <=95 mg per deciliter [5.3 mmol per liter]) versus standard glycemic care alone	subject with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes	open-label
lifestyle modification versus control
US-DDP (lifestyle) (Knowler), 2002	lifestyle-modification intervention versus placebo	nondiabetic patients with elevated glucose and high risk for diabetes	open Follow-up duration: 2.8 years
metformin versus placebo
US-DPP (metformin) (Knowler), 2002	metformin 850mg twice daily versus placebo	nondiabetic patients with elevated glucose and high risk for diabetes	double blind Follow-up duration: 2.8 years USA
n-3 fatty acid supplement versus placebo
GRACE - ORIGIN (n-3 fatty acid),	n-3 fatty acid supplemen versus placebo	subjects with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes	double-blind Follow-up duration: 4.9y (median)
nateglinide versus placebo
NAVIGATOR nateglinide, 2010 NCT00097786	nateglinide 60mg 3 times daily versus placebo	subjects with impaired glucose tolerance and either CV disease or CV risk factors	double-blind Follow-up duration: 5 years 40 countries
ramipril versus placebo
DREAM ramipril, 2006 NCT00095654	ramipril up to 15 mg daily versus placebo	patients with impaired fasting glucose or impaired glucose tolerance, or both, and no previous cardiovascular disease	double blind Follow-up duration: 3 y (median) 21 countries
rosiglitazone versus placebo
DREAM rosiglitazone, 2006 NCT00095654	rosiglitazone 8 mg daily versus placebo	patients with impaired fasting glucose or impaired glucose tolerance, or both	double blind Follow-up duration: 3 years (median) 21 countries
rosiglitazone and metformin versus placebo
CANOE, 2010 NCT00116932	rosiglitazone (2 mg) and metformin (500 mg) twice-daily versus placebo	patients with impaired glucose tolerance	double-blind Follow-up duration: 3.9y (median)
valsartan versus placebo
NAVIGATOR valsartan, 2010 NCT00097786	valsartan up to 160 mg daily versus placebo	subjects with impaired glucose tolerance and either CV disease or CV risk factors	double-blind Follow-up duration: 5 years 40 countries
voglibose versus placebo
Voglibose Ph-3, 2009 UMIN 000001109-	voglibose 0.2 mg three times daily versus placebo	patients with impaired fasting glucose	double blind Follow-up duration: 4.01 years Japan